Participation of Relative or Surrogate in the Patient's Care in Reanimation (PARTICIPATE)

January 27, 2020 updated by: Assistance Publique - Hôpitaux de Paris

ICUs have always perceived by the public has a very technical unit with a restricted and/or forbidden access. Physical alteration of the patient, seeing the patient sedated, the large numbers of devices, the alarms and an uncertain prognosis. All this factors can be perceived by people close to the patient as a source of stress. In the literature, numerous studies have shown that families develop anxiety and depression symptoms while their loved one is hospitalized in the ICU. French intensive care societies thought of ways to prevent or diminish these symptoms. The 6th consensus conference on " Live better in the ICU " recommends: effective and adapted information, large visiting hours to reach an unrestricted access and family participation in care.

The unit has taken this path to improve patient and family centered care by: creating a welcome leaflet, a room dedicated to meetings with families and an ICU open 24/7bto families, with the possibility for children to visit their parents. Hence, spontaneously, relatives have expressed the wish to participate to certain care and when participating, expressed their satisfaction. This observation and testimonies from family members and patients led us to think about the impact of participation of care. Two major French studies have shown contradictory outcomes: 16% of families would have been willing to participate in the first study against 97% in the second one. These studies were survey done after the ICU discharge.

No study today has assessed the actual impact of family participation in care. The aim of this clinical trial is to diminish anxiety and depression symptoms. By participating in care, relatives can develop or strengthen a relationship of trust with caregivers. It could contribute also to a better understanding of the plan of care and an easier context to announce negative outcomes.

Study Overview

Detailed Description

Randomisation visit - D1:

After checking the eligibilities criteria, a member of the staff will explain to the patient and his relative or surrogate the purpose and the planning of the study. The inform consent will be signed by the physician of the study. Two informs consents will be signed : one by the patient and the other one by the relative or surrogate. The randomisation will be done after collecting these consents.

After the draw, the subjects will be randomized either in the control group "Conventional support" or the experimental group "Intervention".

Questionnaires to be completed by the :

  • relatives or surrogates: Hospital Anxiety and Depression scale (HAD scale), Multidimensional Fatigue Inventory (MFI20), Zarit Burden Interview (ZARIT sale) , Beck Depression Inventory (Beck), State-Trait Anxiety Scale (STAI) and "preliminary"
  • patient if possible: HAD scale

Admission + 10 days visit:

Questionnaires to be completed by the relatives or surrogates: HAD scale, MIF20, ZARIT, Beck, STAI and "discharge"

ICU discharge visit :

Questionnaires to be completed by the :

  • relatives or surrogates: HAD scale, MIF20, ZARIT, Beck, STAI and "discharge"
  • patient if possible: HAD scale

Medical staff:

In order to evaluate the feeling of the ICU staff, a satisfaction questionnaire will be propose at the beginning and at the end of the study.

Study Type

Interventional

Enrollment (Anticipated)

140

Phase

  • Not Applicable

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Locations

      • Paris, France, 75013
        • Hopital Pitie Salpetriere

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

18 years and older (Adult, Older Adult)

Accepts Healthy Volunteers

No

Genders Eligible for Study

All

Description

Inclusion criteria

  1. An adult related to the ICU patients, giving his written consent to participate to the study
  2. Being present at the patient's bedside at least twice a week
  3. Speaking and writing comprehension of the french language
  4. Adult ICU patient, admitted in the ICU for less than 72 hours, whatever its pathology
  5. Predictable ICU stay over a week

Exclusion criteria

  1. Refusal of the relative or surrogate
  2. Refusal of the patient
  3. The relative or surrogate can't be present at the patient's bedside at least twice a week
  4. Relative or surrogate already participating in the care of the patient for a chronic disease

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

  • Primary Purpose: Other
  • Allocation: Randomized
  • Interventional Model: Parallel Assignment
  • Masking: None (Open Label)

Arms and Interventions

Participant Group / Arm
Intervention / Treatment
Active Comparator: Conventional arm
The relative or surrogate will not be encouraged to perform care. The management of the relative or surrogate wi ll not changed from the regular standard of the ICU.
The relative or surrogate will not be encouraged to perform care. The management of the relative or surrogate wi ll not changed from the regular standard of the ICU.
Experimental: The relative/surrogate will be encouraged to perform care

The relative or surrogate will perform at least two cares a week . A manual will be given to the relative or surrogate, explaining the different care he can choose to perform on the patient.

The care proposed are: feeding, mouth care, hair wash, shaving, eye care, hand, foot and face massage.

All care are planned and perform under the supervision or/and in collaboration with a caregiver.

Each care is written down on a collecting sheet.

The relative or surrogate will perform at least two cares a week among feeding, mouth care, hair wash, shaving, eye care, hand, foot and face massage.

All care are planned and perform under the supervision or/and in collaboration with a caregiver.

The relative or surrogate will give his opinion by completing the study questionnaires.

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Change from baseline HAD scale at ICU's discharge
Time Frame: From baseline and at the patient's discharge from the ICU assessed up to 3 months

HAD Scale : The primary outcome measure is the relative or surrogate HAD (Hospital Anxiety and Depression Scale) score evolution.

The expected result is a reduction by two points of the total HAD score through active participation in care.

From baseline and at the patient's discharge from the ICU assessed up to 3 months

Secondary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Evolution of the relative or surrogate anxiety/depression
Time Frame: at baseline and after 10 days of ICU hospitalization.
The relative or surrogate will complete the HAD scale and other anxiety/depression questionnaires.
at baseline and after 10 days of ICU hospitalization.
Evolution of the relative or surrogate anxiety/depression
Time Frame: at baseline and at ICU's discharge assessed up to 3 months
The relative or surrogate will complete the HAD scale questionnaires and anxiety/depression questionnaires.
at baseline and at ICU's discharge assessed up to 3 months
Evaluation of the satisfaction's relatives or surrogates regarding their participation in the ICU patient care by a questionnaire
Time Frame: At the patient's ICU discharge assessed up to 3 months
Concern different aspects of the patient's management: listening skills and support from the ICU team, medical information about the patient, benefits and difficulties encountered while participating in care
At the patient's ICU discharge assessed up to 3 months
Evaluation of the satisfaction of the ICU staff by a questionnaire
Time Frame: Through study completion an average of 12 months

Evaluate the feeling of the ICU staff regarding participation in care of surrogates and assess its evolution at the end of the study.

The ICU staff can describe which benefits and difficuties they encountered while caring for the patient with the relative or surrogate.

At initiation visit and at closing of the center

Through study completion an average of 12 months
Quantify which care have been realized by the relatives or surrogates
Time Frame: Through study completion an average of 12 months

Each time a relative or surrogate is caring for the patient, the ICU staff will write it on a specific sheet.

At the end of the study, all this data will be gathered to see which care have been done more often

Through study completion an average of 12 months
HAD scale of the patient
Time Frame: At the ICU discharge assessed up to 3 months
The patient completes the HAD scale if his mental state allows it
At the ICU discharge assessed up to 3 months

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Investigators

  • Principal Investigator: Alain COMBES, M.D, Ph.D, Assistance Publique - Hôpitaux de Paris

Publications and helpful links

The person responsible for entering information about the study voluntarily provides these publications. These may be about anything related to the study.

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (Actual)

November 16, 2017

Primary Completion (Actual)

November 15, 2019

Study Completion (Anticipated)

February 1, 2020

Study Registration Dates

First Submitted

February 6, 2017

First Submitted That Met QC Criteria

March 21, 2017

First Posted (Actual)

March 27, 2017

Study Record Updates

Last Update Posted (Actual)

January 28, 2020

Last Update Submitted That Met QC Criteria

January 27, 2020

Last Verified

January 1, 2020

More Information

Terms related to this study

Plan for Individual participant data (IPD)

Plan to Share Individual Participant Data (IPD)?

NO

Drug and device information, study documents

Studies a U.S. FDA-regulated drug product

No

Studies a U.S. FDA-regulated device product

No

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Clinical Trials on Anxiety Depression

Clinical Trials on Conventional ,care

3
Subscribe